Labcorp shares edge up on beating estimates, raising guidance

Labcorp reported Q3 2026 revenue of $3.81B, exceeding estimates by 1.2% and growing 6.9% YoY. Adjusted EPS was $4.78, a 2.9% beat. The company raised full-year revenue and EPS guidance. Operating margin remained steady at 10.6%, while free cash flow margin improved to 10.8%. Organic revenue grew 5.5% YoY.

Labcorp reported Q3 2026 revenue of $3.81B, up 6.9% YoY, and adjusted EPS of $4.78, up 14.5%. Net income was $262.8M. The company raised full-year guidance for revenue growth and adjusted EPS to $18.30–$18.70. Diagnostics and Biopharma segments showed growth, and Labcorp announced FDA approvals and acquisitions.

LABCORP HOLDINGS INC. (LH) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Contact: Nickolo Russo - Investors Racquel White - Media Investor@labcorp.com Media@labcorp.com Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance • Results from operations for third quarter 2026 versus third quarter 2025: ◦ Re

Labcorp Holdings reported Q3 Non-GAAP EPS of $4.78, exceeding estimates by $0.14. Revenue was $3.81B, up 7.0% Y/Y and $50M above expectations. The company raised full-year revenue growth guidance to 5.9% to 6.7% and adjusted EPS guidance.

Labcorp (LH) reported Q3 2026 revenue of $3.81B, up 6.9% YoY, and adjusted EPS of $4.78, up 14.5%. The company raised full-year guidance, with revenue growth now expected between 5.9% and 6.7%, and adjusted EPS between $18.30 and $18.70. Labcorp also announced several acquisitions and FDA approvals for new diagnostic tests.

Labcorp reported 7% Q3 revenue growth, 14.5% adjusted EPS growth, and raised 2026 guidance. The company invested $255.5M in acquisitions and declared a $0.72 quarterly dividend, according to the press release.